uniQure (NASDAQ:QURE) Receives $17.00 Average Price Target from Analysts

Shares of uniQure (NASDAQ:QURE) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.00.

A number of brokerages have recently weighed in on QURE. Raymond James restated an “outperform” rating and issued a $20.00 target price on shares of uniQure in a research note on Thursday, October 10th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of uniQure in a research note on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 target price on shares of uniQure in a research note on Wednesday, November 6th. StockNews.com upgraded uniQure to a “sell” rating in a research note on Thursday, October 17th. Finally, Royal Bank of Canada lowered their target price on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th.

uniQure Stock Down 1.1 %

QURE opened at $5.78 on Wednesday. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $281.73 million, a price-to-earnings ratio of -1.18 and a beta of 0.90. The business has a 50 day moving average of $5.93 and a 200-day moving average of $5.94.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. As a group, sell-side analysts anticipate that uniQure will post -3.81 earnings per share for the current year.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. abrdn plc boosted its holdings in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after buying an additional 1,528,581 shares during the last quarter. Vanguard Group Inc. lifted its stake in uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after purchasing an additional 109,740 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after purchasing an additional 752,889 shares during the last quarter. Privium Fund Management B.V. lifted its stake in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in uniQure by 133.1% in the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after acquiring an additional 350,291 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.